Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge
Open Access
- 2 April 2013
- journal article
- Published by Springer Nature in Virology Journal
- Vol. 10 (1) , 1-11
Abstract
The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral genome sequences, especially in the viral envelope (Env160). Since it is not possible to directly match the vaccine strain to the vast number of circulating HIV-1 strains, it is necessary to develop an HIV-1 vaccine that can protect against a heterologous viral challenge. Previous studies from our group demonstrated that a mixture of wild type clade B Envgp160swere able to protect against a heterologous clade B challenge more effectively than a consensus clade B Envgp160vaccine. In order to broaden the immune response to other clades of HIV, in this study rhesus macaques were vaccinated with a polyvalent mixture of purified HIV-1 trimerized consensus Envgp140proteins representing clades A, B, C, and E. The elicited immune responses were compared to a single consensus Envgp140representing all isolates in group M (Con M). Both vaccines elicited anti- Envgp140IgG antibodies that bound an equal number of HIV-1 Envgp160proteins representing clades A, B and C. In addition, both vaccines elicited antibodies that neutralized the HIV-1SF162isolate. However, the vaccinated monkeys were not protected against SHIVSF162p4challenge. These results indicate that consensus Envgp160vaccines, administered as purified Envgp140trimers, elicit antibodies that bind to Envgp160sfrom strains representing multiple clades of HIV-1, but these vaccines did not protect against heterologous SHIV challenge.Keywords
This publication has 45 references indexed in Scilit:
- The origin and diversity of the HIV-1 pandemicTrends in Molecular Medicine, 2012
- Vaccination against Heterologous R5 Clade C SHIV: Prevention of Infection and Correlates of ProtectionPLOS ONE, 2011
- Computational Design of Centralized HIV-1 GenesCurrent HIV Research, 2010
- Immunodominant HIV-Specific CD8+T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV ControllersJournal of Virology, 2010
- Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant SystemsVaccine, 2010
- Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 AdjuvantJournal of Virology, 2010
- Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-LJournal of Virology, 2010
- The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDSVaccine, 2008
- Centralized HIV-1 Envelope Immunogens and Neutralizing AntibodiesCurrent HIV Research, 2007
- Antibodies, viruses and vaccinesNature Reviews Immunology, 2002